Financial Data and Key Metrics Changes - Adjusted earnings per share (EPS) for the second quarter was $2.97, exceeding guidance by $0.11 [5][34] - Total net revenues reached $15.4 billion, surpassing expectations by over $400 million, reflecting a 6.5% operational growth [6][34] - Full-year revenue guidance raised to $60.5 billion, an increase of $800 million, with a total increase of $1.5 billion since the start of the year [6][35] - Adjusted EPS guidance for the full year increased by $0.21, now expected between $11.88 and $12.08 [7][35] Business Line Data and Key Metrics Changes - Immunology revenues exceeded $7.6 billion, with SKYRIZI global sales at $4.4 billion, up 61.8% operationally [10][11] - RINVOQ global sales reached $2 billion, reflecting a 41.2% operational growth [12][13] - Neuroscience revenues were approximately $2.7 billion, up 24% operationally, driven by Vraylar and UBRELVY [19][20] - Oncology revenues were nearly $1.7 billion, with IMBRUVICA sales down 9.5% and VENCLEXTA sales up 8.3% [15][16] - Aesthetics revenues were nearly $1.3 billion, down 8% operationally, impacted by economic challenges [17][18] Market Data and Key Metrics Changes - SKYRIZI continues to gain market share in psoriatic disease, with leadership in psoriasis therapy lines [10][11] - RINVOQ is capturing significant patient share in IBD, with strong uptake in ulcerative colitis and Crohn's disease [12][13] - HUMIRA sales declined to over $1.1 billion, down 58.2% due to biosimilar competition [14] - The aesthetics market is underperforming historical levels, with economic challenges affecting consumer sentiment [18][19] Company Strategy and Development Direction - The company is focused on advancing its pipeline and strategic transactions to support long-term growth [5][9] - Recent acquisitions include Gubra for obesity treatment and KapStan Therapeutics for CAR T platform [8][9] - The company aims to enhance its immunology pipeline with innovative therapies and technologies [25][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong outlook for 2025 and beyond, supported by robust performance across key products [10][38] - The company is well-positioned to navigate economic challenges and capitalize on growth opportunities in various therapeutic areas [19][38] Other Important Information - The company has executed over 30 business development transactions since the beginning of the previous year [8] - Regulatory submissions for new therapies are anticipated, including RINVOQ for alopecia areata and vitiligo [24][25] Q&A Session Summary Question: Impact of Stellara biosimilar on SKYRIZI and RINVOQ - Management noted that while there may be some impact, the core momentum for SKYRIZI and RINVOQ is driven by strong data and physician connections [41][42] Question: Confidence in SKYRIZI and RINVOQ long-term guidance - Management indicated that they are tracking well against long-term guidance and will update it at the appropriate time [47][48] Question: Leveraging global aesthetics footprint for obesity drugs - The company sees a strong opportunity to integrate obesity treatments into its aesthetics practices, capitalizing on existing patient flow [66][68] Question: Status of anti-amyloid monoclonal antibody - The company is evaluating the potential for a registrational trial based on imaging as an endpoint, but specific details were not disclosed [94]

智通财经7月31日电，生物制药公司艾伯维股价迅速拉升，现涨幅超3%。 ...

Core Viewpoint - AbbVie reported a 6.6% year-over-year revenue growth to $15.42 billion, exceeding analyst expectations of $15.03 billion [1] - Adjusted earnings per share (EPS) were $2.97, also above the forecasted $2.88 [1] Revenue Breakdown - Global sales of the immunology drug Humira fell 58% to $1.18 billion, with a more significant decline in the U.S. market [1] - Strong sales performance from the new arthritis drug Skyrizi, with global sales soaring 62% to $4.42 billion [1] Future Guidance - AbbVie expects adjusted EPS for the year to be between $11.88 and $12.08, an increase from the previous estimate of $11.67 to $11.87 [1]

Core Viewpoint - AbbVie (ABBV.US) reported better-than-expected Q2 results and raised its full-year earnings forecast, driven by newer immunology drugs offsetting the significant decline in sales of its blockbuster arthritis treatment Humira [1] Financial Performance - Q2 revenue reached $15.42 billion, a year-over-year increase of 6.6%, exceeding market expectations by $390 million [1] - Non-GAAP EPS was $2.97, surpassing market expectations by $0.06 [1] - Adjusted Q2 gross margin was 84.4%, and operating margin was 44.3% [1] Product Performance - Global immunology product net revenue was $7.631 billion, with reported baseline growth of 9.5% and operational baseline growth of 9.2% [1] - Humira's net revenue plummeted 58% year-over-year to $1.2 billion, while Skyrizi and Rinvoq generated $4.4 billion and $2 billion in revenue, respectively, with year-over-year growth of approximately 62% and 42% [1] - The neuroscience product portfolio achieved net revenue of $2.7 billion, a year-over-year increase of about 24% [1] - Sales of the leukemia treatment Imbruvica, developed in collaboration with Johnson & Johnson, declined by 10% year-over-year, but the oncology product portfolio's net revenue increased by $1.7 billion, reflecting a year-over-year growth of about 3% [1] Guidance Update - AbbVie raised its adjusted diluted EPS guidance for 2025 from the previous range of $11.67-$11.87 to $11.88-$12.08, with market consensus expectations at $11.98 [1]

每经AI快讯，7月31日，艾伯维盘前股价涨超3%，因其上调财年每股收益指引。 （文章来源：每日经济新闻） ...

格隆汇7月31日｜艾伯维(ABBV.US)预计全年调整后EPS为11.88美元至12.08美元，此前预期为11.67美元 至11.87美元。 ...

智通财经7月31日电，艾伯维盘前股价涨超3%，因其上调财年每股收益指引。 ...

二季度经调整后每股收益2.97美元，上年同期2.65美元。 艾伯维二季度净利润154.2亿美元，预估150亿美元。 ...

生物制药巨头 艾伯维(AbbVie)上调2024财年调整后 每股收益指引至11.88-12.08美元，原预期为11.67- 11.87美元。 ...

FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2025 ABBVIE INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________ (Exact name of registrant as specified in its charter) (State or other Jurisdiction (Commission File Number) (IRS Employer Delaware 001-35565 32-0375147 of Incorporation) Identification No.) 1 North Waukegan Road Nor ...